Coronavirus Disease-2019 in the Immunocompromised Host
Copyright © 2022 Elsevier Inc. All rights reserved..
Immunocompromised hosts, which encompass a diverse population of persons with malignancies, human immunodeficiency virus disease, solid organ, and hematologic transplants, autoimmune diseases, and primary immunodeficiencies, bear a significant burden of the morbidity and mortality due to coronavirus disease-2019 (COVID-19). Immunocompromised patients who develop COVID-19 have a more severe illness, higher hospitalization rates, and higher mortality rates than immunocompetent patients. There are no well-defined treatment strategies that are specific to immunocompromised patients and vaccines, monoclonal antibodies, and convalescent plasma are variably effective. This review focuses on the specific impact of COVID-19 in immunocompromised patients and the gaps in knowledge that require further study.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:44 |
|---|---|
| Enthalten in: |
Clinics in chest medicine - 44(2023), 2 vom: 21. Juni, Seite 395-406 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bertini, Christopher D [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Completed 25.04.2023 Date Revised 11.05.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ccm.2022.11.012 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM35588982X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM35588982X | ||
| 003 | DE-627 | ||
| 005 | 20231226065313.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ccm.2022.11.012 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1186.xml |
| 035 | |a (DE-627)NLM35588982X | ||
| 035 | |a (NLM)37085228 | ||
| 035 | |a (PII)S0272-5231(22)00128-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bertini, Christopher D |c Jr |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Coronavirus Disease-2019 in the Immunocompromised Host |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.04.2023 | ||
| 500 | |a Date Revised 11.05.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Elsevier Inc. All rights reserved. | ||
| 520 | |a Immunocompromised hosts, which encompass a diverse population of persons with malignancies, human immunodeficiency virus disease, solid organ, and hematologic transplants, autoimmune diseases, and primary immunodeficiencies, bear a significant burden of the morbidity and mortality due to coronavirus disease-2019 (COVID-19). Immunocompromised patients who develop COVID-19 have a more severe illness, higher hospitalization rates, and higher mortality rates than immunocompetent patients. There are no well-defined treatment strategies that are specific to immunocompromised patients and vaccines, monoclonal antibodies, and convalescent plasma are variably effective. This review focuses on the specific impact of COVID-19 in immunocompromised patients and the gaps in knowledge that require further study | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Hematologic malignancy | |
| 650 | 4 | |a Immunocompromised host | |
| 650 | 4 | |a Immunosuppression | |
| 650 | 4 | |a Pneumonia | |
| 650 | 4 | |a SARS-CoV-2 | |
| 700 | 1 | |a Khawaja, Fareed |e verfasserin |4 aut | |
| 700 | 1 | |a Sheshadri, Ajay |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinics in chest medicine |d 1991 |g 44(2023), 2 vom: 21. Juni, Seite 395-406 |w (DE-627)NLM012973599 |x 1557-8216 |7 nnns |
| 773 | 1 | 8 | |g volume:44 |g year:2023 |g number:2 |g day:21 |g month:06 |g pages:395-406 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ccm.2022.11.012 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 44 |j 2023 |e 2 |b 21 |c 06 |h 395-406 | ||